** Shares of drug developer Actuate Therapeutics ACTU.O rise 7.2% to $10.6 premarket
** ACTU's experimental drug, elraglusib, in combination with chemotherapy met the main goal of statically significant improvement in overall survival in a mid stage trial, compared to chemotherapy alone
** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body
** Co says the drug helped patients survive for a year
** Up to last close, ACTU stock up 24.25% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.